Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 2984-2997

  Reles, Angela ^a,c   Wen, Wen H ^a   Gee, Conway ^a   Press, Michael F ^b   Schmider, Annette ^c   Kilian, Uta ^c   Minguillon, Carmen ^c   Schönborn, Ines ^c   Lichtenegger, Werner ^c   Runnebaum, Ingo B ^d   Kreienberg, Rolf ^d   Jones, Lovell A ^e   El Naggar, Adel ^f   Reich, Olaf ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT, NEWBORN; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034796867     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Cancer Statistics 1998
2. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva and vagina
3. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
4. p53 mutations in ovarian cancer: A late event?
5. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy
6. p53 gene mutation is a common genetic event in ovarian carcinoma
7. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer
8. p53 gene mutations and protein accumulation in human ovarian cancer
9. p53 gene mutations in human borderline epithelial ovarian tumors
10. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas
11. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry
12. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
13. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
14. An abundance of p53 null mutations in ovarian carcinoma
15. ARG→STOP mutations of the TP53 gene in human ovarian cancer in the southwestern part of the Netherlands
16. p53 mutations and expression in ovarian cancers: Correlation with overall survival
17. Clinical implication of basic research: Cancer therapy meets p53
18. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms
19. Mutation and overexpression of p53 in early stage epithelial ovarian cancer
20. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinoma than in other common epithelial tumors of the human ovary
21. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance
22. p53 mutation in a series of epithelial ovarian cancers from the U.K. and its prognostic significance
23. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor
24. TP53 protein accumulation and gene mutation in relation to overexpression of mdm2 protein in ovarian borderline tumours and stage I carcinomas
25. p53 gene analysis of ovarian borderline tumors and stage I carcinomas
26. Ovarian cancer genomic instability correlates with p53 frameshift mutations
27. Exon 5 of the p53 gene is a target for deletions in ovarian cancer
28. Overexpression and mutation of P53 in epithelial ovarian cancer
29. Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression
30. p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry
31. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study
32. Quantification of p53 in epithelial ovarian cancer
33. 6-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer
34. p53 accumulation in ovarian carcinomas and its prognostic implications
35. Prognostic significance of p53 immunostaining in epithelial ovarian cancer
36. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas
37. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma
38. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
39. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma
40. The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients
41. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer
42. p53 is a persistent and predictive marker in advanced ovarian carcinomas: Multivariate analysis including comparison with Ki67 immunoreactivity
43. Prognostic significance of p53 and p21 immunoreactivity in epithelial cancers of the ovary
44. The prognostic significance of p53 expression quantified by computerized image analysis in epithelial ovarian cancer
45. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer
46. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
47. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance
48. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53
49. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocy-clohexane)(trans-diacetato)(dichloro)-platinum(IV)
50. Annual report on the results of treatment in gynecologic cancer: Statements of the results obtained in patients, 1982 to 1986, inclusive 3-and 5-year survival up to 1990
51. Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry
52. Protocols for an improved detection of point mutations by SSCP
53. DNA sequencing with chain-terminating inhibitors
54. Thermal cycle dideoxy DNA sequencing
55. Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples
56. Nonparametric estimation from incomplete observations
57. Statistical aspects of the analysis of data from retrospective studies of disease
58. Regression models and life-tables
59. Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers
60. Clonal origin of epithelial ovarian carcinoma: Analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation
61. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
62. Structural aspects of the p53 protein in relation to gene evolution: A second look
63. Immunostaining of p53 protein in ovarian carcinoma: Correlation with histopathological data and clinical outcome
64. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer
65. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer
66. Regulation of p53 stability by mdm2
67. Mdm2 promotes the rapid degradation of p53
68. Inactivation of p53 in human ovarian cancer cell lines increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis
69. Effects of p53 status on sensitivity to platinum complex in human ovarian cancer cell lines
70. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer
71. Identification of p53 genetic suppressor elements which confer resistance to cisplatin
72. Sensitization of cisplatinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas
73. An information-intensive approach to the molecular pharmacology of cancer
74. p53 status and the efficacy of cancer therapy in vivo
75. Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure
76. Drug resistance in ovarian cancer-the role of p53